Evidence map›Paper›PMID 42064142›Full record

ArticleJournal of oral and maxillofacial pathology : JOMFP

Immunohistochemical evaluation of PD-1 and PD-L1 in oral squamous cell carcinoma and oral epithelial dysplasia.

Somanathan Anjana, Rajendran Rajeev

Abstract read
In one paragraph

Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Somanathan AnjanaDepartment of Oral Pathology and Microbiology, Government Dental College, Trivandrum, Kerala, India.
Rajendran RajeevDepartment of Oral Pathology and Microbiology, Government Dental College, Trivandrum, Kerala, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Oral squamous cell carcinoma (OSCC) is one of the most common cancers globally, accounting for a significant portion of head and neck malignancies. Most cases are preceded by oral potentially malignant disorders (OPMD), which may progress through histological changes such as hyperplasia, hyperkeratosis, and oral epithelial dysplasia (OED). A key factor in this progression is immune evasion, particularly through the PD-1/PD-L1 pathway, which tumour cells exploit to escape immune surveillance. Although therapeutic strategies targeting PD-1/PD-L1 are promising, their expression patterns and prognostic significance in OED and OSCC remain underexplored. This study aimed to evaluate and compare the immunohistochemical expression of PD-1 and PD-L1 in OED and OSCC, including their different grades. Methods: An analytical cross-sectional study was conducted with 66 samples (33 each of OED and OSCC). Diagnoses were confirmed histopathologically. Samples were stained using immunohistochemistry for PD-1 and PD-L1, and expression was assessed using the immunoreactivity score (IRS). Statistical analysis was performed using SPSS version 20. Results and Discussion: PD-1 and PD-L1 expression were significantly higher in OSCC compared with OED ( Conclusion: These findings highlight the potential role of the PD-1/PD-L1 axis in early tumour development and immune evasion. Further research with larger sample sizes and clinical correlation could establish PD-1/PD-L1 as targets for immunotherapy, potentially improving outcomes in advanced OSCC and severe dysplasia.

Indexed as

Immune checkpointsimmune markersimmunohistochemistryoral epithelial dysplasiaoral squamous cell carcinomaPD-1PD-L1

Identifiers

PMID42064142
PMCPMC13127718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.